Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Centessa Pharmaceuticals PLC has received a consensus recommendation of "Buy" from twelve analysts, with an average target price of $31.45.
• Insider selling activity was noted, with executives selling a total of 171,322 shares worth approximately $2.47 million in the last three months.
• Despite positive analyst ratings, Centessa Pharmaceuticals stock has seen a 7.9% decline recently and its share price currently stands at $15.91.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) has been given an average rating of "Buy" by the thirteen research firms that are covering the stock, Marketbeat Ratings reports. Twelve analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $31.4545.

A number of research firms have commented on CNTA. Chardan Capital reaffirmed a "buy" rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an "outperform" rating and a $40.00 target price on the stock. Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price on the stock. Wells Fargo & Company started coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday. They set an "overweight" rating and a $31.00 price target on the stock. Finally, Truist Financial started coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $30.00 price target on the stock.

Centessa Pharmaceuticals Trading Down 0.4%

NASDAQ CNTA traded down $0.06 during trading hours on Thursday, reaching $15.73. The company had a trading volume of 950,166 shares, compared to its average volume of 988,284. The stock has a 50-day moving average of $15.99 and a 200 day moving average of $14.46. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $19.09. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $2.11 billion, a P/E ratio of -8.79 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $17.23, for a total transaction of $103,380.00. Following the sale, the general counsel owned 105,386 shares of the company's stock, valued at approximately $1,815,800.78. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $15.92, for a total transaction of $875,600.00. Following the sale, the chief executive officer directly owned 221,017 shares in the company, valued at $3,518,590.64. This represents a 19.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 171,322 shares of company stock worth $2,472,814 over the last ninety days. Company insiders own 7.09% of the company's stock.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in CNTA. China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company's stock valued at $252,000 after acquiring an additional 870 shares in the last quarter. Exome Asset Management LLC raised its holdings in Centessa Pharmaceuticals by 17.0% in the second quarter. Exome Asset Management LLC now owns 166,944 shares of the company's stock valued at $2,194,000 after acquiring an additional 24,200 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in Centessa Pharmaceuticals by 24.8% in the second quarter. Octagon Capital Advisors LP now owns 1,030,000 shares of the company's stock valued at $13,534,000 after acquiring an additional 205,000 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Centessa Pharmaceuticals by 3,028.1% in the second quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company's stock valued at $460,000 after acquiring an additional 33,854 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Centessa Pharmaceuticals in the second quarter valued at approximately $16,052,000. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.